Jennifer Erdrich

Interests

No activities entered.

Courses

Scholarly Contributions

Chapters

• Erdrich, J. (2024). Surgical Options for Breast Cancer and Consent Guidelines for Indigenous Women. In Indigenous and Tribal Peoples and Cancer. Springer.
• Erdrich, J. (2024). Item writer for the 2024-2025 This Week in SCORE’s Breast Cancer quiz. In The SCORE Portal.
• Erdrich, J. (2024). Item writer for the 2024-2025 This Week in SCORE’s Skin Cancers quiz. In The SCORE Portal.
• Erdrich, J., & Essner, R. (2024). Item writers for the TWIS Skin Cancer Quiz. In The SCORE Portal.
• Asare, E., Erdrich, J., & Gershenwald, J. (2023). Melanoma – Wide Excision. In The SCORE Portal.
• Erdrich, J. (2023). Simple, Modified Radical, and Radical Mastectomy. In The SCORE Portal.
• Erdrich, J., Farrow, N., & Beasley, G. (2023). Sentinel Lymph Node Biopsy for Melanoma. In The SCORE Portal.
• Erdrich, J., & Subhedar, P. (2022). Excisional Breast Biopsy and Partial Mastectomy. In The SCORE Portal. http://www.surgicalcore.org. Published October 2022. Accessed October 24, 2022.
• Perez, M. C., Russell, M. C., & Erdrich, J. (2022). Ilioinguinal-Femoral Lymphadenectomy. In The SCORE Portal.
• Erdrich, J. (2007). Alcoholism, Suicide, and Drug Addiction among American Indians. In National Museum of the American Indian. Harper Collins Publisher.
• Erdrich, J. (2007). Are Indians more prone to certain diseases? National Museum of the American Indian. In National Museum of the American Indian. Smithsonian Institution: Harper Collins Publications.

Journals/Publications

• Erdrich, J., Cordova-Marks, F. M., Carson, W. O., Bea, J. W., Montfort, W. R., & Thomson, C. A. (2024). Health Behavior Change Intervention Preferences Expressed by American Indian Cancer Survivors From a Southwest Tribal Community: Semistructured Interview Study. JMIR formative research, 8, e51669.
  More info

  While many factors, including social determinants of health, affect cancer mortality, one modifiable risk factor that may contribute to cancer disparities is obesity. The prevalence of obesity in the American Indian/Alaska Native population is 48.1% per the Centers for Disease Control and Prevention. The overall cancer mortality for the American Indian/Alaska Native population is 18% higher than the White population as reported by the American Cancer Society. Interventions tailored to American Indian/Alaska Native communities that promote healthy lifestyle behaviors after cancer diagnosis and prior to cancer surgery (prehab) might improve cancer outcomes for this population.
• Erdrich, J., Cordova-Marks, F. M., Carson, W., Bea, J. W., Montfort, W. R., & Thomson, C. A. (2024). Health behavior change intervention preferences expressed by American Indian cancer survivors from a Southwest tribal community . JMIR Cancer.
• Shirzad, S., Tran, T., Carlson, Q., LeBeau, L., Chalkey, S., Donohue, C., & Erdrich, J. (2024). Leiomyoma of Nipple: Review, Case Report, and Surgical Treatment . ACS Case Reviews in Surgery.
• Wang, T., Chai, B., Chen, W. Y., Holmes, M. D., Erdrich, J., Hu, F. B., Rosner, B. A., Tamimi, R. M., Willett, W. C., Kang, J. H., & Eliassen, A. H. (2024). Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses’ Health Studies . International Journal of Cancer.
• Wang, T., Chai, B., Chen, W. Y., Holmes, M. D., Erdrich, J., Hu, F. B., Rosner, B. A., Tamimi, R. M., Willett, W. C., Kang, J. H., & Eliassen, A. H. (2024). Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies. International journal of cancer, 155(2), 211-225.
  More info

  We aimed to examine the association between the use of metformin and other anti-diabetic medications and breast cancer incidence within two large prospective cohort studies. We followed 185,181 women who participated in the Nurses' Health Study (NHS; 1994-2016) and the NHSII (1995-2017), with baseline corresponding to the date metformin was approved for type 2 diabetes (T2D) treatment in the US Information on T2D diagnosis, anti-diabetes medications, and other covariates was self-reported at baseline and repeatedly assessed by follow-up questionnaires every 2 years. Breast cancer cases were self-reported and confirmed by medical record review. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between medication use and breast cancer were estimated using Cox proportional hazards regression models, adjusting for breast cancer risk factors. During 3,324,881 person-years of follow-up, we ascertained 9,192 incident invasive breast cancer cases, of which 451 were among women with T2D. Compared with women without T2D (n = 169,263), neither metformin use (HR = 0.97; 95% CI = 0.81-1.15) nor other anti-diabetic medications use (HR = 1.11; 95% CI = 0.90-1.36) associated with significantly lower breast cancer incidence. Among women with T2D (n = 15,918), compared with metformin never users, metformin ever use was not significantly inversely associated with breast cancer (HR = 0.92; 95% CI = 0.74-1.15). Although we observed that past use of metformin was inversely associated with breast cancer in the T2D population (HR = 0.67; 95% CI = 0.48-0.94), current use (HR = 1.01; 95% CI = 0.80-1.27) and longer duration of metformin use were not associated with breast cancer (each 2-year interval: HR = 1.01; 95% CI = 0.95-1.07). Overall, metformin use was not associated with the risk of developing breast cancer among the overall cohort population or among women with T2D.
• Fernandez, J. M., Mata, E. M., Erdrich, J., & Fazel, M. (2023). Retrospective Cohort Analysis of Sex Differences in American Indians and Alaska Natives With Invasive Melanoma From the National Cancer Database. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 49(11), 1039-1041.
• Taber, P., Armin, J. S., Orozco, G., Del Fiol, G., Erdrich, J., Kawamoto, K., & Israni, S. T. (2023). Artificial Intelligence and Cancer Control: Toward Prioritizing Justice, Equity, Diversity, and Inclusion (JEDI) in Emerging Decision Support Technologies. Current oncology reports, 25(5), 387-424.
  More info

  This perspective piece has two goals: first, to describe issues related to artificial intelligence-based applications for cancer control as they may impact health inequities or disparities; and second, to report on a review of systematic reviews and meta-analyses of artificial intelligence-based tools for cancer control to ascertain the extent to which discussions of justice, equity, diversity, inclusion, or health disparities manifest in syntheses of the field's best evidence.
• Tulk, A., Watson, R., & Erdrich, J. (2023). The Influence of Statin Use on Chemotherapeutic Efficacy in Studies of Mouse Models: A Systematic Review. Anticancer Research, 43(10), 4263-4275. doi:10.21873/anticanres.16621
• Wang, Z., Li, W., Jiang, Y., Tran, T., Cordova, L., Chung, J., Kim, M., Wondrak, G., Erdrich, J., & Lu, J. (2023). Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy . Nature Communications, 14(1), 7235. doi:10.1038/s41467-023-43079-4
• Cordova-Marks, F. M., Carson, W. O., Monetathchi, A., Little, A., & Erdrich, J. (2022). Native and Indigenous Populations and Gastric Cancer: A Worldwide Review. International Journal of Environmental Research and Public Health, 19(9).
  More info

  Gastric cancer is a worldwide concern, particularly for Indigenous populations who face greater disparities in healthcare. With decreased access to screening and critical treatment delays, this group is experiencing adverse health effects. To determine what factors drive these disparities, a systematic review was performed in PubMed. This revealed a lack of research on gastric cancer specific to this population. The literature primarily focused on subset analyses and biological aspects with sparse focus on determinants of health. The results informed this presentation on factors related to Indigenous gastric cancer, which are influenced by colonialism. Indigenous populations encounter high rates of food shortage, exposure to harmful environmental agents, structural racism in the built environment, , and compromised healthcare quality as an effect of colonialism, which all contribute to the gastric cancer burden. Putting gastric cancer into a cultural context is a potential means to respond to colonial perspectives and their negative impact on Indigenous patients. The objective of this manuscript is to examine the current state of gastric cancer literature from a global perspective, describe what is currently known based on this literature review, supplemented with additional resources due to lack of published works in PubMed, and to present a model of gastric cancer through the lens of a modified medicine wheel as a potential tool to counter colonial healthcare perspectives and to honor Indigenous culture.
• Erdrich, J. (2022). ASO Author Reflections: Mastectomy Versus Lumpectomy: Are There Surgical Disparities for Native American Women Compared with White Women?. Annals of surgical oncology, 29(2), 1031-1032.
• Erdrich, J., Cordova-Marks, F., Monetathchi, A. R., Wu, M., White, A., & Melkonian, S. (2022). Disparities in Breast-Conserving Therapy for Non-Hispanic American Indian/Alaska Native Women Compared with Non-Hispanic White Women. Annals of surgical oncology, 29(2), 1019-1030.
  More info

  Little is known about the surgical patterns of American Indian/Alaska Native (AI/AN) breast cancer patients. The purpose of this study is to determine whether there are disparities in breast cancer surgery and radiation therapy between non-Hispanic AI/AN (NH-AI/AN) women and non-Hispanic White (NHW) women.
• Erdrich, J., Lourdault, K., Judd, A., Kaufman, D., Gong, K. W., Gainsbury, M., Deng, N., Shon, W., & Essner, R. (2022). Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential. The Journal of surgical research, 279, 682-691.
  More info

  Histologic characteristics cannot adequately predict which patients are at risk of developing metastatic disease after excision of primary cutaneous melanoma. The aim of this study was to identify immunomodulatory genes in primary tumors associated with development of distant metastases.
• Judd, A., Weinkauf, C., & Erdrich, J. (2022). Subclavian Vein Stenosis Imitating Inflammatory Breast Cancer. Cureus, 14(12). doi:10.7759/cureus.32184
• Watson, R., Tulk, A., & Erdrich, J. (2022). The Link Between Statins and Breast Cancer in Mouse Models: A Systematic Review. Cureus, 14(11). doi:10.7759/cureus.31893
• Cordova-Marks, F., Fennimore, N., Bruegl, A., & Erdrich, J. (2020). What Should Physicians Consider About American Indian/Alaska Native Women's Reproductive Freedom?. American Medical Association Journal of Ethics, 22(10), E845-850.
  More info

  Historically, American Indians and Alaska Natives (AI/AN) have been subjected to a lack of control over various aspects of their lives, including their reproductive health. In discussions of family planning with AI/AN patients, clinicians must consider past violations of reproductive rights and the need for transparent consent. This article explores the following questions: What were historical violations of AI/AN women's reproductive rights? How should physicians express respect for this history and for the autonomy of AI/AN female patients regarding surgical sterilization procedures today?
• Erdrich, J., & Gonzales, C. R. (2020). How Should Health Professions Schools Partner With AI/AN Communities?. AMA journal of ethics, 22(10), E851-855.
  More info

  Many health professions education institutions exist on land once inhabited by American Indians and Alaska Natives (AI/AN). Land acknowledgment by these academic organizations is helpful, but collaborative support of AI/AN health is also needed. Because tribal-university partnerships in education are fewer than in research but just as important, this article considers health professions schools' responsibilities to offer students clinical rotations on tribal lands and to recruit AI/AN students. Such investment expands student educational opportunity, diversifies clinical workforces, and helps tribes improve health infrastructure and sustainability. This article also offers an adaptable roadmap for building such partnerships.
• Erdrich, J., Jecius, H., Junak, M., & Kikuchi, S. (2020).

  Cutaneous Metastasis in the Setting of Both Colon and Breast Primary Malignancies

  . Case Reports in Gastrointestinal Medicine, 2020, 1-4. doi:10.1155/2020/8852459
• Erdrich, J., Schaberg, K. B., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., & Beausang, J. F. (2018). Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. Cold Spring Harbor molecular case studies, 4(5).
  More info

  Neuroendocrine tumors (NETs) arising from tailgut cysts are a rare but increasingly reported entity with gene expression profiles that may be indicative of the gastrointestinal cell of origin. We present a case report describing the unique pathological and genomic characteristics of a tailgut cyst NET that metastasized to liver. The histologic and immunohistochemical findings were consistent with a well-differentiated NET. Genomic testing indicates a germline frameshift in and a few somatic mutations of unknown significance. Transcriptomic analysis suggests an enteroendocrine L cell in the tailgut as a putative cell of origin. Genomic profiling of a rare NET and metastasis provides insight into its origin, development, and potential therapeutic options.
• Gainsbury, M. L., Erdrich, J., Taubman, D., Mirocha, J., Manguso, N., Amersi, F., & Silberman, A. W. (2018). Prevalence and Predictors of Preoperative Venous Thromboembolism in Asymptomatic Patients Undergoing Major Oncologic Surgery. Annals of surgical oncology, 25(6), 1640-1645.
  More info

  Postoperative venous thromboembolism (VTE) is a leading cause of in-hospital mortality for cancer patients; however, the prevalence of preoperative VTE remains unclear.
• Melkonian, S. C., Jim, M. A., Reilley, B., Erdrich, J., Berkowitz, Z., Wiggins, C. L., Haverkamp, D., & White, M. C. (2018). Incidence of primary liver cancer in American Indians and Alaska Natives, US, 1999-2009. Cancer causes & control : CCC, 29(9), 833-844.
  More info

  To evaluate liver cancer incidence rates and risk factor correlations in non-Hispanic AI/AN populations for the years 1999-2009.
• Erdrich, J., Kastenberg, Z. J., DiMaio, M. A., Longacre, T. A., & Rhoads, K. F. (2015). Collateral damage: taxane-induced colonic perforation. Digestive diseases and sciences, 60(2), 313-5.
• Erdrich, J., Zhang, X., Giovannucci, E., & Willett, W. (2015). Proportion of colon cancer attributable to lifestyle in a cohort of US women. Cancer causes & control : CCC, 26(9), 1271-1279.
  More info

  Many modifiable lifestyle factors have been associated with colon cancer risk, but less is known about their effect on disease when considered together. Estimating the proportion of colon cancer cases that could be prevented by the adoption of combined modifiable lifestyle behaviors will provide important insights into disease prevention.
• Yang, R. L., Esquivel, M., Erdrich, J., Lau, J., Melcher, M. L., & Wapnir, I. L. (2014). PREDICT: Instituting an Educational Time Out in the Operating Room. Journal of graduate medical education, 6(2), 382-3.

Presentations

• Erdrich, J. (2024, February). Caring for Native American Patients (panel member). Medical Student Orientation. Tucson, AZ: University of Arizona, College of Medicine-Tucson.
• Erdrich, J. (2022, April). Skin Cancer in American Indians/Alaska Natives. Keynote Address for Annual Skin Cancer Institute. University of Arizona Cancer Center.
• Erdrich, J. (2023, April). Let's Talk About Cancer: Breast Cancer. Community event for Pascua Yaqui hosted by El Rio Health; The University of Arizona Cancer Center Community Outreach & Engagement. Tucson, AZ: The University of Arizona Cancer Center.
• Erdrich, J. (2023, February). Caring for Native American Patients (panel member). Medical Student Orientation. Tucson, AZ: University of Arizona, College of Medicine-Tucson.
• Erdrich, J. (2023, September). Pathways to Surgery. AED Presentation (UA Pre-professional health honor society). Tucson, AZ: The University of Arizona.
• Erdrich, J. (2022, June). Zigzags in Native American Cancer Research. SIMinar for The Summer Institute on Medical Ignorance Research Program.
• Erdrich, J. (2022, May). Data Blitz Presentation: Mastectomy vs Lumpectomy --  Are There Surgical Disparities for Native American women with breast cancer. COM-T Research Day. University of Arizona College of Medicine.
• Erdrich, J. (2022, May). Native American Cancer Disparities . Dept of Surgery Research Day Guest Speaker. University of Arizona.
• Erdrich, J. (2022, November). Current Models of Care for Indigenous People. Cancer Prevention in Indigenous Communities (CPIC). Virtual Meeting: National Institutes of Health.
• Erdrich, J. (2022, November). My Zigzag Journey Becoming a Surgical Oncologist . My Journey Series: Partnership for Native American Cancer PreventionNACP.
• Erdrich, J. (2022, October). Let's Talk About Cancer. Breast Cancer Awareness Month. Tucson, AZ: University of Arizona Cancer Center.
• Erdrich, J. (2022, October). Tribal Cancer Coalition: Skin Cancer in American Indians/Alaska Natives. Tribal Cancer Coalition. Tucson, AZ (Virtual Meeting): Arizona Department of Health Services.
• Erdrich, J. (2020, Apr). Let’s Talk About Cancer (invited speaker). Native American Cancer Prevention; University of Arizona Cancer Center. Nationally Presented Webinar: University of Arizona Cancer Center.
• Erdrich, J. (2020, Oct). 13th Annual ADHS Arizona Tribal Collaborative on Cancer Roundtable (Invited virtual panelist). 13th Annual ADHS Arizona Tribal Collaborative on Cancer. Phoenix, AZ: Arizona Department of Health Services and the University of Arizona Cancer Center.
• Erdrich, J. (2019, Nov). Answering the Call for More Native Physicians (invited panelist). Association of American Medical Colleges (AAMC) Annual Conference. Phoenix, AZ: Association of American Medical Colleges (AAMC).
• Erdrich, J. (2019, Nov). Cancer Trends in Indian Country (invited speaker). NACP Tribal Cancer Speaker Series; Partnership for Native American Cancer Prevention (NACP). Tucson, AZ: University of Arizona (Web-Ex Nationally Presented).
• Erdrich, J. (2019, Nov). Skin Cancer in AI/AN (invited speaker). 12th Annual Arizona Tribal Collaborative on Cancer. Phoenix, AZ: Arizona Department of Health Services and the University of Arizona Cancer Center.
• Erdrich, J. (2019, Oct). Landmark Papers Session (invited panelist). Association of Women Surgeons Annual Meeting. San Francisco, CA: Association of Women Surgeons.
• Erdrich, J. (2019, September). Native American Cancer Burden: The Influence of Dollars, Distance, and Diplomacy. University of Arizona – Tucson, Department of Surgery Grand Rounds. Tucson, AZ: University of Arizona.

Poster Presentations

• Cordova-Marks, F., Carson, W., Monetathchi, A., Little, A., & Erdrich, J. (2022, March). A Worldwide Review: Indigenous Populations and Gastric Cancer. 2022 MEZCOPH Public Health Poster Forum. Tucson, AZ.
• Cordova-Marks, F., Carson, W., Monetathchi, A., Little, A., & Erdrich, J. (2022, Nov). Through an Indigenous Lens: Gastric Cancer Worldwide. 2022 Cancer Prevention in Indigenous Communities: Screening to Follow Up. Tucson, AZ.
• Erdrich, J., Eliassen, A. H., Willett, W. C., Tamimi, R. M., Rosner, B. A., Hu, F. B., Giovannucci, E. L., Holmes, M. D., Chen, W. Y., Chai, B., Kang, J. H., & Wang, T. (2022). Abstract 5902: Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses’ Health Studies. Cancer Research.
  More info

  Abstract Background: Type 2 diabetes (T2D) has been associated with increased risk of breast cancer. However, the role of metformin, the first-line anti-diabetic drug, in breast cancer carcinogenesis has not been elucidated completely. We aimed to examine further the association between the use of metformin and other anti-diabetic medication and breast cancer incidence within two large prospective cohort studies. Methods: We followed 184,437 women who participated in the Nurses’ Health Study (NHS;1994-2016) and the NHSII (1995-2017), with the baseline tied to the date metformin was introduced into the United States market. Information on T2D diagnosis, metformin, and other anti-diabetic medication, and other covariates were self-reported at baseline and repeatedly assessed by follow-up questionnaires every two to four years. Breast cancer cases were self-reported and confirmed by medical record review. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between metformin/other anti-diabetic medication use and breast cancer incidence were estimated using Cox proportional hazards regression models. Results: During 3,412,366 person-years of follow-up, we ascertained 9,442 incident invasive breast cancer cases, of which 720 were among women with T2D. Compared with women without T2D (n=168,498), similar risks of developing breast cancer were observed among those who ever used metformin (HR =0.95; 95%CI=0.79-1.13) and among those who received medications other than metformin (HR =1.11; 95%CI=0.91-1.37). Among women with T2D (n=15,939), compared with never metformin users, ever use of metformin overall was not associated with breast cancer (HR =0.90; 95%CI=0.72-1.13), but a lower risk of breast cancer was observed among past metformin users (HR =0.72; 95%CI=0.52-0.99). Longer duration of metformin use was not associated with risk of breast cancer (each 2-year interval: HR =0.98; 95%CI=0.93-1.03, p-trend=0.32). However, among women with substantial weight increase since age 18 (>25 kg), greater than 5 years of metformin use was associated with a lower risk of breast cancer (HR =0.62; 95%CI=0.43-0.89). Conclusion: Although we observed inverse associations among past metformin users, similar associations were not found among current users. Overall, metformin use was not strongly associated with the risk of developing breast cancer among the general cohort population or among women with T2D. Citation Format: Tengteng Wang, Jae H. Kang, Boyang Chai, Wendy Y. Chen, Michelle D. Holmes, Jennifer Erdrich, Edward L. Giovannucci, Frank B. Hu, Bernard A. Rosner, Rulla M. Tamimi, Walter C. Willett, A. Heather Eliassen. Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses’ Health Studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5902.
• Whittaker, M., Whittaker, M., Farr, K., Farr, K., Potluri, P., Potluri, P., Foster, N., Foster, N., Erdrich, J., Erdrich, J., Segar, J., Segar, J., Ehsani Chimeh, S., Ehsani Chimeh, S., Jiralerspong, S., Jiralerspong, S., Roe, D., Roe, D., Chalasani, P., & Chalasani, P. (2022, December). Physician Practice Patterns of Breast Imaging After Treatment: Survey of Real-World Practice. San Antonio Breast Cancer Symposium. San Antonio Texas.
• Erdrich, J., Gong, K., Kaufman, D., Deng, N., & Essner, R. (2018, Oct). Microarray Gene Expression of the Primary Tumor Predicts Sentinel Lymph Node Disease. The 15th International Congress of the Society for Melanoma Research. Manchester, England.